Obsessive-Compulsive Disorder (OCD)
Recent research indicates that psychedelics, particularly psilocybin, are emerging as potential therapeutic agents in the treatment of Obsessive-Compulsive Disorder (OCD). Early clinical trials demonstrate promising results regarding their efficacy and safety, paving the way for future studies in this field.
Key Insights
- 1
Recent evidence suggests that psilocybin can reduce OCD symptoms in treatment-resistant cases, offering a new hope for this challenging condition.
- 2
Psychedelics are thought to promote neuroplasticity and facilitate new perspectives, potentially addressing the rigid thought patterns inherent in OCD.
- 3
Existing clinical trials are exploring optimal dosing protocols and treatment regimens to enhance therapeutic outcomes for OCD patients.
What is Obsessive-Compulsive Disorder (OCD)?
Obsessive-Compulsive Disorder (OCD) is characterised by persistent, intrusive thoughts (obsessions) that lead to repetitive behaviours or mental acts (compulsions) aimed at alleviating the distress caused by these obsessions.
The pathophysiology of OCD is believed to involve abnormalities in neural circuits, particularly those involving the orbitofrontal cortex, anterior cingulate cortex, and striatum, with imbalances in neurotransmitter systems, notably serotonin and dopamine.
Common symptoms include excessive cleaning, checking, counting, and arranging, which can significantly impair an individual's daily functioning and quality of life.
Current Treatments
Standard treatments for OCD include selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine and sertraline, and cognitive behavioural therapy (CBT), particularly exposure and response prevention.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Obsessive-Compulsive Disorder (OCD).
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Clinical trials indicate a consistent reduction in OCD symptoms with psilocybin in treatment-resistant patients. | Medium | Moderate | Consistent |
| MDMA Limited research exists on MDMA's effects specifically for OCD, with emerging studies highlighting potential benefits. | Small | Low | Inconsistent |
| Ketamine Ketamine's antidepressant effects provide some hope, but specific evidence for OCD is currently limited. | Small | Low | Inconsistent |
Psilocybin and Obsessive-Compulsive Disorder (OCD)
Psilocybin has exhibited promising results in treating obsessive-compulsive disorder (OCD) through facilitated introspection and changes in perception. Its action on serotonin receptors is believed to promote cognitive flexibility, reducing the grip of intrusive thoughts on patients and allowing for greater engagement in therapeutic processes. Preliminary trials support its safety and efficacy in diminishing OCD symptoms, opening pathways for further investigation.
MDMA and Obsessive-Compulsive Disorder (OCD)
Though primarily investigated for trauma-related disorders, MDMA also shows potential in enhancing therapeutic interactions and emotional resonance during psychotherapy for OCD. By promoting feelings of empathy and connection, MDMA may assist patients in confronting their compulsions within a supportive context, although specific studies on its efficacy for OCD are still emerging.
Clinical Outlook
The future of psychedelic treatment in OCD is promising, with ongoing clinical trials focused on psilocybin and other compounds indicating potential for significant symptom relief. As understanding of the mechanisms underlying OCD improves, tailored psychedelic therapies may evolve, leading to novel treatment paradigms.
Industrial Landscape
Key players in psychedelic OCD research include Stanford University's OCD Research Lab led by Carolyn Rodriguez and various non-profits such as the International OCD Foundation, which encourages research and awareness.
Quick Indicators
Organisations
Search →COMPASS Pathways
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
Ketamine Research Institute
The Ketamine Research Institute is a US-based clinical research organization developing precision medicine approaches to ketamine infusion therapy, studying optimized dosing protocols to treat depression and offering clinician training in evidence-based ketamine practice.
University of California, San Francisco
University of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.
Imperial College London
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
Centre for Addiction and Mental Health
The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health teaching hospital, located in Toronto, Ontario. CAMH is a major hub for psychedelic research in Canada, running trials on psilocybin, MDMA, and ketamine across a range of psychiatric indications.
Usona Institute
Usona Institute is a US-based 501(c)(3) non-profit medical research organisation (MRO) headquartered in Madison, Wisconsin. Co-founded in 2014 by Bill Linton (CEO of Promega Corporation) and Malynn Utzinger, M.D., Usona was established after Linton witnessed the profound impact of a Johns Hopkins psilocybin study on a terminally ill friend. Unlike commercial drug developers, Usona operates as a mission-driven MRO — conducting and supporting pre-clinical and clinical research on psilocybin and other consciousness-expanding medicines, with the goal of developing accessible, affordable treatments. Its research leadership includes Dr. Charles Raison (Director of Clinical and Translational Research, UW-Madison psychiatrist) and Dr. Alexander Sherwood (medicinal chemist). Usona's psilocybin programme received FDA Breakthrough Therapy Designation for major depressive disorder in 2019. After completing the Phase 2 PSIL201 study (the largest Phase 2 randomised controlled trial of psilocybin for MDD at the time), the Institute launched the Phase 3 uAspire trial in 2024 — a 240-participant, randomised, double-blind, multicentre study comparing 25 mg psilocybin vs placebo in adults with MDD. Usona is also exploring 5-MeO-DMT in early-stage research.
University of Arizona
Although the University of Arizona may not have a dedicated psychedelic research group, one of the first modern clinical trials investigating the use of psychedelics to treat a mental disorder was conducted at the University. In 2006, Dr Francisco Moreno led the first FDA-approved study in 25 years using psychedelics at UA. The study examined the use of psilocybin to treat symptoms of obsessive-compulsive disorder (OCD). Since then, researchers within the Department of Psychiatry at UA have maintained their interest in the field. Dr Moreno, along with Dr Brian Bayze and their research group, is continuing to conduct research into this particular area of psychedelic science at UA ever since the 2006 trial. There is a trial underway at UA exploring the effects of psilocybin on OCD.
Johns Hopkins University
The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
Stanford University
At the Stanford School of Medicine, researchers from the Rodriguez Lab and the Heifets Lab have united under the banner of the Stanford Psychedelic Science Group. Their primary clinical focus is to investigate compounds including ketamine, psilocybin, and MDMA as potential treatments for debilitating disorders such as obsessive-compulsive disorder (OCD), treatment-resistant depression, and post-traumatic stress disorder (PTSD).
Yale University
In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
Arizona Biomedical Research Commission (ABRC)
The Arizona Biomedical Research Commission (ABRC) is a state government body within the Arizona Department of Health Services that funds biomedical research, having become the first state agency in the US to direct $5 million toward randomized controlled clinical trials of psilocybin whole mushrooms for conditions including PTSD, depression, and addiction. The ABRC oversees the Arizona Psilocybin Research Advisory Council and has since expanded its psychedelic research portfolio to include an additional $5 million for ibogaine clinical trials.
People
Search →Federico Cavanna
Researcher in psychedelic science / neuroscientific researcher (exact current title not confidently verified)
He is a coauthor on multiple widely cited studies on psilocybin microdosing, DMT, and psychedelic use, helping characterize subjective, behavioral, and cognitive effects of psychedelics.
Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Joost Breeksema
Postdoctoral researcher and Executive Director of the OPEN Foundation
He is a prominent psychedelic researcher and advocate whose work helps shape evidence-based psychedelic policy, ethics, and patient-centered understanding of psychedelic and ketamine/esketamine treatments.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Kate Godfrey
Research Associate at Imperial College London’s Centre for Psychedelic Research
Kate Godfrey is notable for contributing to leading human psychedelic research on microdosing, neuroimaging, and neuroplasticity at Imperial College London.
John Kelly
Associate Professor / Consultant General Psychiatrist at Trinity College Dublin
John R. Kelly is a leading academic psychiatrist in Ireland whose work has helped shape modern psychedelic psychiatry, including psilocybin research across depression, service-user attitudes, and transdiagnostic treatment frameworks.
Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Laura Alethia de la Fuente
Postdoctoral researcher in neuroscience at CONICET / Instituto de Física de Buenos Aires (IFIBA-UBA)
She co-authored several notable human psychedelic studies on psilocybin microdosing, DMT, and acute psilocybin effects, contributing both behavioral and neurophysiological evidence in the field.
Christopher Davoli
Associate Professor of Psychology at Central Michigan University
He is a cognitive psychologist whose work with colleagues has helped document acute and longer-term effects of psychedelics on perception, experience, and psychological outcomes.
Tomislav Majic
Senior physician and Head of the Psychotropic Substances Research Group at Charité – Universitätsmedizin Berlin
He is a psychiatrist and psychedelics researcher at Charité who has helped lead clinical and observational work on serotonergic psychedelics and related substances, including their therapeutic potential and risks.
Scott Tyler Aaronson
Chief Science Officer, Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt; Adjunct Professor of Psychiatry, University of Maryland School of Medicine
He is a leading psychiatrist in treatment-resistant depression and a key investigator on psilocybin studies, including work on preparation, dosing, outcomes, and mechanisms of psychedelic-assisted therapy.
Connected Evidence
The latest clinical data and verified academic findings associated with Obsessive-Compulsive Disorder (OCD).